Vinda International Holdings Limited



(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3331)

2016 Interim Results Investor Presentation








Key Accomplishments

Key Accomplishments in 1H2016



Ambition

To become a leading hygiene company in Asia








(НК\$М)	1H2016	1H2015	Change
Revenue*	5,666	4,743	+19.5%
Gross profit	1,772	1,497	+18.4%
EBITDA	831	702	+18.3%
Operating profit	515	468	+9.9%
Net profit	321	331	-2.9%
Basic earnings per share (HK cents)	30.6	33.1	
Proposed interim dividend per share (HK cents)	5.0	5.0	

* Organic revenue growth: 14.5%¹

¹Excluding acquisition and exchange rate effects





Enlarged Personal Care Portfolio




	1H2015	2H2015	1H2016	1H2016	
Revenue				Organic revenue g	rowth ³
Tissue	4,583 (97%)	4,774 (96%)	4,923 <i>(</i> 87% <i>)</i>	Tissue	14%
Personal Care	160 (3%)	178 (4%)	743 (13%) ¹	Personal Care	22%
Total	4,743 (100%)	4,952 (100%)	5,666 (100%)	Total	14.5%
Gross margin					
Tissue	31.7%	29.6%	31.5%		
Personal Care	26.2%	26.5%	29.7%		
Total	31.6%	29.5%	31.3%		
Segment results ² margin					
Tissue	12.3%	9.4%	11.1%		
Personal Care	(28.2%)	(29.1%)	5.4%		

¹ Personal care accounted for 4% and 21% of total revenue in 1Q16 and 2Q16 respectively

² Segment results: segment profit before amortisation of trademarks, licenses & contractual customer relationship

³ Excluding acquisition and exchange rate effects







Items Affecting Comparability (HK\$M)	1H2016	1H2015
Operating items:		
Foreign exchange gain/ (loss)	(14)	(32)
 Amortisation of the acquired intangible assets related to the acquisition on 1 Apr 2016 (non-cash item)² 	(14)	-
Transaction cost related to acquisition	(3)	-
Financing items:		
Foreign exchange gain/ (loss)	(1)	2
Fair value downward adjustment on convertible note (non-cash item)	(18)	-

¹ Excluding items affecting comparability

² It will only be presented as an item affecting comparability where it was not included in comparative prior year period







Effective Tax Rate

- - Increase in SG&A ratio
 - Due to the amortisation of the acquired \geq intangible assets related to the acquisition on 1 Apr 2016 (non-cash item)
 - Due to the continuing commitment to brand \geq building & promotional activities for Vinda brand, new brands & personal care business

- Increase in effective tax rate, mainly due to:
 - Non-tax deductible items \geq including fair value downward adjustment on convertible note

Key Ratios

(HK\$M)	As at 30 Jun 2016	As at 31 Dec 2015	As at 30 Jun 2015
Debtors turnover days	44	43	45
Creditors turnover days	66	79	71
Finished turnover days	45	43	40
Working capital to sales ratio	14%	14%	16%
(HK\$M)	As at 30 Jun 2016	As at 31 Dec 2015	As at 30 Jun 2015
Cash and cash equivalents ¹	632	393	514
Total borrowings ²	5,666	4,739	4,528
Borrowings in CNY (%)	61%	42%	10%
Net debt	5,035	4,345	4,014
Net gearing ratio ³ (%)	74%	88%	76%
Interest coverage ⁴ (times)	5.8	6.2	7.4

1 20

As at 30 June 2016:

- Total outstanding loans from SCA: HK\$1.8 B
- Total unutilized credit facilities (incl. unutilized loan from SCA): HK\$5.7 B

1. Incl. restricted bank deposit. 2. Total borrowings (incl. SCA shareholder loan)

4 94

-1 20

Lower	

gearing level

HK\$390M net proceeds from share placement in May 2016

Reduced FX exposure by increasing proportion of CNY loans




^{3.} Total borrowing less bank balances and cash and restricted deposits / total shareholders' equity. 4. Underlying EBIT/interest (times), excluding interest capitalisation factor.

Rapid Growth in E-commerce




Revenue¹ (by sales channels)



- Traditional channels (i.e. Distributiors)
- B2B (i.e. Corporate clients)
- Modern channels (i.e. Hypermarkets, Supermarkets)
- E-Commerce


¹ Excluding the acquired sales in 2016



Enhanced Tissue Mix



Tissue Revenue¹ (by categories)




¹Excluding the acquired sales in 2016

²Excluding acquisition & exchange rate effects

Future Outlook


Mid-Long Run Growth Catalysts





Strong Market Positions






- 4. According to SCA's internal estimates
- 5. Kantar Worldpanel Malaysia, MAT 16 May 2016
- 6. Nielsen volume for 12 months ending 31 May 2016

Strong Supply Chain Support





17

Our Priorities

Ambition

To become a leading hygiene company in Asia



Drive Tissue business in China

- Drive Tissue sales in China with innovativedriven product R&D & marketing campaigns
- Increase contribution from
 Tempo in high-end market

Broaden the Personal Care presence in China

- Become the leader in Incontinence with TENA & Dr. P
- Establish feminine as a future profit contributor
- Selective presence in competitive baby market





Vind

Drive Personal Care growth in Asia & roll out tissue

- Strengthen Personal Care market positions where we have presence
- Roll out tissue to Asia by leverage the strong route to market

Core Principles





Sustainability

- Consumer-focused
- Technology-focused
- Leverage global
 technological platform

Integrity



- 100% certified pulp
- Reduce energy consumption
- Reduce water usage



Innovation

- Good corporate
 governance
- Code of conduct
- Compliance



Q&A

Disclaimer



Information contained in our presentation is intended solely for your personal reference and is strictly confidential. Such information is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning the company and/or its business. We make no representation or warranty, express or implied, regarding, and assumes no responsibility or liability for, the fairness, accuracy, correctness or completeness of, or any errors or omissions in, any information or opinions contained herein.

In addition, the information contains projections and forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the company's assumptions are correct. Actual results may differ materially from those projected. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.

This presentation does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.



Thank You



